CASI - BioInvent's BI-1206 restores activity of rituximab in non-hodgkin's lymphoma patients

BioInvent International (BOVNF) and partner CASI Pharmaceuticals (CASI) announce positive interim results from the Phase I/IIa trial of novel anti-Fc?RIIB antibody BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) in patients with indolent relapsed or refractory B-cell non-Hodgkin's lymphoma ((NHL)).Of the 9 patients who completed the induction cycle, 6 patients have shown either complete or partial responses.Two patients achieved a complete response, which continues to be sustained 12 and 24 months later.Another patient who had a blastoid form of MCL achieved a partial response, and a complete depletion of peripheral tumor cells. Readout from two patients is still pending.A total of 15 patients have been recruited to date in the Phase I dose escalation part of the study.No dose-limiting toxicities have been observed."We continue to be excited about this anti-Fc?RIIB antibody's potential in restoring rituximab's activity in NHL patients, and these results provided further encouraging evidence of its potential as a durable

For further details see:

BioInvent's BI-1206 restores activity of rituximab in non-hodgkin's lymphoma patients